To our knowledge, ours is the first study to clarify the differences in subjects with NAFLD having elevation of ALT at various stage of MS, as well as measuring differences in metabolites with respect to NAFLD having elevation of ALT in the context of medical check-ups. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.